Adicet Bio : Investor Presentation

Published: 2021-10-13 11:22:14 ET ACET

Allogeneic Gamma Delta T Cells Engineered to Fight Cancer

Forward-Looking Statements

This presentation contains "forward-looking statements" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business and operations of Adicet including, but not limited to, express or implied statements regarding preclinical and clinical development of Adicet's product candidates, including future plans or expectations for ADI-001 and ADI-002 and potential therapeutic effects of ADI-001 and ADI-002, the timing and outcome of discussions with FDA and other regulatory agencies, expectations regarding the design, implementation, timing, and success of its current and future clinical studies of ADI -001, and ADI-002 including whether they are pivotal or would support registration, expectations regarding its other CAR T cell therapy development activities, Adicet's growth as a company and the anticipated contribution of the members of its board of directors to its operations and progress, and its expectations regarding its uses of capital, expense s, future accumulated deficit and other second quarter 2021 financial results. Any forward-looking statements in this presentation are based on management's current expectatio ns and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of COVID-19 on Adicet's business and financial results, including with respect to disruptions to its clinical trials, business operations, and ability to raise additional capital; Adicet's ability to execute on its strategy; that positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; future clinical studies may fail to demonstrate adequate safety and efficacy o f our product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization; regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time- consuming, and inherently unpredictable; regulatory developments in the United States and foreign countries; Adicet's estimates regarding expenses, future revenue, and capital requirements; as well as those risks and uncertainties set forth in Adicet's most recent annual report on Form 10-K and subsequent filings with the Securities and Exchange Commission (SEC). For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Adicet's most recent annual report on Form 10-K and our periodic reports on Form 10-Q and Form 8-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Adicet's other filings with the SEC. All information in this presentation is as of the date its release, and Adicet undertakes no duty to update this information unless required by law.

Industry and Market Information

Information regarding market share, market position and industry data pertaining to Adicet's business contained in this presentation consists of estimates based on data and reports compiled by industry professional organizations and analysts and Adicet's knowledge of their industry. Although Adicet believes the industry and market data to be reliable, this

information could prove to be inaccurate. You should carefully consider the inherent risks and uncertainties associated with the market and other industry data contained in this presentation. Forward-looking information obtained from third-party sources is subject to the same qualifications and the additional uncertainties as the other forward-looking statements in this presentation.

Adicet Bio: Leaders in Engineered Gamma-DeltaCAR-T Cell Therapy

CAR: Chimeric Antigen Receptors; NK: Natural Killer; GvHD: Graft Versus Host Disease; MHC: Major Histocompatibility

3 Complex; NKG2D: NK Group 2D; NCR=Natural Cytotoxicity Receptors; DNAM-1: DNAX accessory molecule-1

Comparison of Gamma Delta 1 vs Gamma Delta 2 T Cells

Feature

Vδ1+

Vδ2+

Comment

T cells

T cells

Diverse VDJ rearranged TCR

Vδ2+ T cells generally express invariant TCR

Programmed adaptations for tissue survival

Vδ1+ T cells tolerate hypoxic and low nutrient conditions

Expression of tumor homing receptors

Vδ1+ T cells express CCR5 and tumor homing receptors

Efficacy

Long lifespan & adaptive immune response

Vδ1+ T cells oligoclonally expand to pathogenic antigens

MHC unrestricted TCR

Vδ1+ T cells recognized antigen independent of MHC

NKG2D & broad NCR expression

Prevents immune escape of tumor cells

High granzyme & perforin expression

Vδ1+ T cells are highly cytolytic (similar to CD8 αβ T cells

Broad anti-tumor toxicity

Vδ1+ T cells recognize numerous malignant cell types

Low / no KIR Expression

Adicet' s Vδ1+ T cells display low inhibitory KIR

Safety and Practicality

GvHD incompatible TCR

Vδ1+ T cells cannot be activated by unmatched MHC

No IL-17 / RORγt expression (Th17)

Adicet' s Vδ1+ T cells never express "protumorigenic" IL-17

or RORγt

Moderate IL-2 expression

Adicet's Vδ1+ T cells don't hyperproliferate

High expansion without exhaustion

Adicet' s Vδ1+ T have potential for 2E11 fold expansion

MHC: major histocompatibility complex, IL- Interleukin, TCR: T cell receptor, NK: natural killer; NCR: natural cytotoxicity receptor, KIR: killer cell immunoglobulin like receptor, Th: T helper

Sources: Nussbaumer, O. & Koslowski, M. Immuno-Oncology Technol. 1, 3-10 (2019); Girardi, M. et al. J. Exp. Med. 198, 747-755 (2003);

4 Girardi, M. et al. Science 294, 605-609 (2001); Gentles, A. et al. Nat. Med. 21, 938-945 (2015); Minculescu, L. et al. Front. Immunol. https://doi.org/10.3389/fimmu.2019.01997 (2019); Godder, K. T. et al. Bone Marrow Transplant. 39, 751-757 (2007).

Adicet Bio Leadership Team

Chen Schor

President and CEO

Blake Aftab, Ph.D.

Chief Scientific Officer

Francesco Galimi,

M.D., Ph.D.

Chief Medical Officer

Don Healey, Ph.D.

Chief Technology Officer

Nick Harvey

Chief Financial Officer

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Adicet Bio Inc. published this content on 13 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 October 2021 15:21:06 UTC.